[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100435439":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":27,"locations":33,"responsibleParty":53,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":97,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Herlev and Gentofte Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Psoriasis patients",null,"Eligible psoriasis patients will be identified from the daily outpatient program, at the Department of Dermato-Allergology, that is the department will provide the patient's contact information to the project group. As most outpatient clinic psoriasis is classified as moderate to severe, in order to approximate a random sample as accurate as possible including patients with mild psoriasis, all people with a diagnosis of psoriasis will a general invitation to participate in the study through appropriate channels such as the Danish Psoriasis Foundation's newsletter.",{"label":13,"type":10,"description":14,"interventionNames":10},"Control group","The control group will consist of a retrospective random sample of around 1.000 patients from the general population examined in the 4th and 5th Copenhagen City Heart Study, 2001-2003 and 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and\u002For paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).",[16,20,23,25],{"name":17,"affiliation":18,"role":19},"Tor Biering-Sørensen, MD, PhD, MPH","Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen","STUDY_DIRECTOR",{"name":21,"affiliation":22,"role":19},"Claus Zachariae, MD, DMSc","Department of Dermato-Allergology, Herlev and Gentofte University Hospital, University of Copenhagen",{"name":24,"affiliation":22,"role":19},"Lone Skov, MD, PhD, DMSc",{"name":26,"affiliation":18,"role":19},"Gunnar Gislason, MD, PhD",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Maria F Dons, MD","CONTACT","+4560604780","mariaflarupdons@hotmail.com",[34],{"facility":18,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Hellerup","Copenhagne","2900","Denmark","DK",{"type":42,"coordinates":43},"Point",[44,45],12.57093,55.73204,{"lat":45,"lon":44},[48,51],{"name":49,"role":30,"phone":31,"phoneExt":10,"email":50},"Maria F Dons, MD, PhD-felllow","maria.flarup.dons.01@regionh.dk",{"name":52,"role":30,"phone":10,"phoneExt":10,"email":10},"Tor Biering-Sørenesn",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Maria Flarup Dons","MD, fellow","100435439","prevalence-and-risk-factors-associated-with-cardiac-comorbidity-in-psoriasis-100435439",false,"NCT04950218","Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA: Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA","Inclusion Criteria:\n\n* Patients 18 years or older with a diagnosis of psoriasis will be invited to participate\n\nExclusion Criteria:\n\n* Patients not able to cooperate to the study\n* Patients unable understand and sign informed consent","ALL","18 Years",{"count":68,"type":69},1000,"ESTIMATED","OBSERVATIONAL","In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.",[73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96],"Psoriasis","Cardiovascular Diseases","Cardiovascular Risk Factor","Cardiovascular Pathology","Psoriasis Vulgaris","Psoriatic Nail","Psoriasis Face","Psoriasis Guttate","Psoriasis Gyrata","Psoriasis Diffusa","Psoriasis Palmaris","Psoriasis Annularis","Psoriasis Circinata","Psoriasis Plantaris","Psoriasis Universalis","Psoriasis Geographica","Left Ventricular Dysfunction","Myocardial Infarction","Myocardial Ischemia","Heart Failure","Stroke","Heart Diseases","Heart Failure, Systolic","Heart Failure, Diastolic",[73,98,99,100,101,102],"Echocardiography","Advanced echocardiography","Biomarkers","Mortality","Cardiovascular mortality","2025-09-09",{"date":105,"type":106},"2025-09-15","ACTUAL",{"date":108,"type":106},"2021-09-01",{"date":110,"type":69},"2034-10-01",{"name":5,"class":6},1]